NCT06430671 - Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Relapsing-remitting Multiple Sclerosis (RRMS)

Interventions

DRUG

CLS12311 low

Peptide-coupled Red Blood Cells (RBCs)

DRUG

CLS12311 medium

Peptide-coupled Red Blood Cells (RBCs)

DRUG

CLS12311 high

Peptide-coupled Red Blood Cells (RBCs)

DRUG

uncoupled RBCs

autologous Red Blood Cells (RBCs)

Trial Locations (8)

Bellevue Medical Group (BMG), Neurozentrum, Zurich

UniversitätsSpital Zürich (USZ), Klinik für Neurologie, Zurich

RS Centrum - Neurologická klinika, Prague

Neurologická klinika 2. LF UK a FN Motol, Prague

Universitätsklinikum Hamburg-Eppendorf (UKE), Klinik für Neurologie, Hamburg

Fraunhofer Institut für Translationale Medizin und Pharmakologie (ITMP), Göttingen

Universitätsklinikum Münster (UKM), Klinik für Neurologie, Münster

Azienda Ospedaliero Universitaria Careggi, Florence